In the first clinical trial (NCT03665155), patients with CD38+ MM cells were administered 89Zr-daratumumab on day 0 and underwent PET/CT imaging on days 1, 2–4, 5–6, and 7–8 [71]. The gene discussed is CD38; the disease is Miyoshi myopathy.